

Supplementary Materials
Consolidated Financial Statements for the year ended
December 31, 2025 (IFRS)



CHUGAI

CHUGAI PHARMACEUTICAL



A member of the Roche group

- Notes: 1. Portions of this report that refer to performance forecasts or any other future events are believed to be reasonable under information available at the time of the forecasts. Actual results may materially differ from these forecasts due to potential risks and uncertainties.
2. Amounts shown in this report are rounded to the nearest 0.1 billion yen. Variance and % are calculated based on the amounts shown.
3. Exchange rates used for each period are as follows.

Weighted average rate*

(Yen)

| | Actual FY2024 | | | | Actual FY2025 | | | | Assumption FY2026 |
|-----|------------------|--------|--------|--------|------------------|--------|--------|--------|----------------------|
| | 1-3 | 1-6 | 1-9 | 1-12 | 1-3 | 1-6 | 1-9 | 1-12 | 1-12 |
| | YTD | YTD | YTD | YTD | YTD | YTD | YTD | YTD | YTD |
| CHF | 162.70 | 160.90 | 160.43 | 161.02 | 172.46 | 171.31 | 171.62 | 173.57 | 184.00 |
| EUR | 161.10 | 164.63 | 163.89 | 163.30 | 159.84 | 162.19 | 165.47 | 168.84 | 179.00 |
| USD | 131.49 | 135.45 | 136.39 | 139.11 | 147.35 | 146.56 | 146.36 | 147.08 | 151.00 |
| SGD | 110.08 | 112.60 | 114.77 | 113.60 | 113.62 | 111.63 | 112.44 | 113.61 | 119.00 |

*Weighted average of the exchange rates used to record foreign currency transactions included in categories from revenue to operating profit

Market average rate

| | Actual FY2024 | | | | Actual FY2025 | | | |
|-----|------------------|--------|--------|--------|------------------|--------|--------|--------|
| | 1-3 | 1-6 | 1-9 | 1-12 | 1-3 | 1-6 | 1-9 | 1-12 |
| | YTD | YTD | YTD | YTD | YTD | YTD | YTD | YTD |
| CHF | 169.79 | 171.06 | 171.46 | 172.00 | 169.60 | 172.12 | 175.95 | 179.98 |
| EUR | 161.11 | 164.43 | 164.26 | 163.81 | 160.38 | 162.03 | 165.29 | 168.68 |
| USD | 148.35 | 152.06 | 151.12 | 151.42 | 152.47 | 148.57 | 148.19 | 149.66 |
| SGD | 110.71 | 112.92 | 112.96 | 113.31 | 113.12 | 112.15 | 113.03 | 114.47 |

Period-end rate

| | Actual FY2024 | | | | Actual FY2025 | | | |
|-----|------------------|---------|---------|---------|------------------|---------|---------|---------|
| | Mar. 31 | Jun. 30 | Sep. 30 | Dec. 31 | Mar. 31 | Jun. 30 | Sep. 30 | Dec. 31 |
| | | | | | | | | |
| CHF | 167.93 | 178.94 | 169.13 | 173.50 | 170.10 | 181.00 | 186.38 | 197.48 |
| EUR | 163.33 | 172.12 | 158.72 | 163.08 | 162.24 | 169.46 | 174.31 | 183.75 |
| USD | 151.39 | 160.83 | 142.18 | 156.83 | 149.84 | 144.76 | 148.63 | 156.47 |
| SGD | 112.12 | 118.41 | 111.05 | 115.27 | 111.61 | 113.41 | 115.21 | 121.82 |

Reconciliation of IFRS results to Core results

(Billions of yen)

| | FY2024 | | | | FY2025 | | | |
|-------------------------------------|--------------|-------------------|--------|--------------|--------------|-------------------|--------|--------------|
| | 1-12 | | | | 1-12 | | | |
| | IFRS results | Intangible assets | Others | Core results | IFRS results | Intangible assets | Others | Core results |
| Revenue | 1,170.6 | – | – | 1,170.6 | 1,257.9 | – | – | 1,257.9 |
| Sales | 997.9 | – | – | 997.9 | 1,077.8 | – | – | 1,077.8 |
| Other revenue | 172.7 | – | – | 172.7 | 180.1 | – | – | 180.1 |
| Cost of sales | (339.4) | 1.3 | – | (338.1) | (363.7) | 1.2 | 11.0 | (351.5) |
| Gross profit | 831.2 | 1.3 | – | 832.5 | 894.3 | 1.2 | 11.0 | 906.5 |
| Research and development | (181.4) | 4.4 | 0.1 | (176.9) | (187.6) | 1.9 | 5.6 | (180.1) |
| Selling, general and administration | (110.1) | – | 7.9 | (102.2) | (116.5) | – | 13.3 | (103.2) |
| Other operating income (expense) | 2.3 | – | 0.4 | 2.7 | 8.6 | – | (8.6) | 0.0 |
| Operating profit | 542.0 | 5.7 | 8.4 | 556.1 | 598.8 | 3.1 | 21.3 | 623.2 |
| Financing costs | 0.0 | – | – | 0.0 | (0.2) | – | – | (0.2) |
| Other financial income (expense) | 1.0 | – | – | 1.0 | (0.8) | – | – | (0.8) |
| Profit before taxes | 543.0 | 5.7 | 8.4 | 557.1 | 597.8 | 3.1 | 21.3 | 622.2 |
| Income taxes | (155.7) | (1.7) | (2.6) | (160.0) | (163.8) | (0.9) | (6.5) | (171.2) |
| Net income | 387.3 | 4.0 | 5.8 | 397.1 | 434.0 | 2.2 | 14.8 | 451.0 |
| Attributable to | 387.3 | 4.0 | 5.8 | 397.1 | 434.0 | 2.2 | 14.8 | 451.0 |
| Chugai shareholders | 387.3 | 4.0 | 5.8 | 397.1 | 434.0 | 2.2 | 14.8 | 451.0 |
| Non-controlling interests | – | – | – | – | – | – | – | – |

Core results

Chugai discloses its results on a Core basis from 2013 in conjunction with its transition to IFRS. Core results are the results after adjusting non-recurring items recognized by Chugai to IFRS results. Chugai's recognition of non-recurring items may differ from that of Roche due to the difference in the scale of operations, the scope of business and other factors. Core results are used by Chugai as an internal performance indicator, for explaining the status of recurring profits both internally and externally, and as the basis for payment-by-results.

The table above shows the reconciliation of IFRS results into Core results. The detail is as below.

Intangible assets

Amortization (1.6 billion yen in 2024 and 1.4 billion yen in 2025)

Impairment (4.1 billion yen in 2024 and 1.7 billion yen in 2025)

Others

Expenses relating to the management decision to collectively discontinue in-house development projects, etc. (None in 2024 and 16.4 billion yen in 2025)

Business rebuilding expenses (7.9 billion yen in 2024 and 13.3 billion yen in 2025)

Restructuring expenses, including gain on sales of non-current assets in conjunction with the closing of a business office. (0.5 billion yen in 2024 and –8.4 billion yen in 2025)

IFRS results (QTD)

(Billions of yen)

| | Actual | | | | Actual | | | | | | | |
|--|--------|--------|--------|--------|--------|--------|--------|---------|---------|--------|--------|--------|
| | FY2024 | | | | FY2025 | | | | | | | |
| | 1-3 | 4-6 | 7-9 | 10-12 | 1-3 | Change | 4-6 | Change | 7-9 | Change | 10-12 | Change |
| | QTD | QTD | QTD | QTD | QTD | (%) | QTD | (%) | QTD | (%) | QTD | (%) |
| Revenue | 236.9 | 315.9 | 315.7 | 302.1 | 288.5 | +21.8 | 290.0 | (8.2) | 333.2 | +5.5 | 346.3 | +14.6 |
| Sales | 204.5 | 281.1 | 264.8 | 247.6 | 259.7 | +27.0 | 251.7 | (10.5) | 283.1 | +6.9 | 283.2 | +14.4 |
| Domestic | 103.2 | 114.0 | 114.5 | 129.5 | 103.0 | (0.2) | 120.4 | +5.6 | 120.4 | +5.2 | 128.6 | (0.7) |
| Overseas | 101.3 | 167.1 | 150.3 | 118.1 | 156.7 | +54.7 | 131.4 | (21.4) | 162.8 | +8.3 | 154.6 | +30.9 |
| Other revenue | 32.5 | 34.9 | 50.9 | 54.5 | 28.7 | (11.7) | 38.3 | +9.7 | 50.0 | (1.8) | 63.1 | +15.8 |
| Royalty income and profit-sharing income | 21.0 | 33.8 | 39.6 | 53.0 | 25.3 | +20.5 | 37.0 | +9.5 | 50.0 | +26.3 | 60.3 | +13.8 |
| of which income from Roche | 20.4 | 33.4 | 38.9 | 52.1 | 24.5 | +20.1 | 35.5 | +6.3 | 47.3 | +21.6 | 56.0 | +7.5 |
| Other operating income | 11.5 | 1.0 | 11.2 | 1.5 | 3.4 | (70.4) | 1.3 | +30.0 | (0.0) | – | 2.7 | +80.0 |
| Cost of sales | (72.9) | (87.9) | (84.2) | (94.3) | (87.8) | +20.4 | (88.1) | +0.2 | (100.2) | +19.0 | (87.6) | (7.1) |
| (% of Sales) | 35.6 | 31.3 | 31.8 | 38.1 | 33.8 | – | 35.0 | – | 35.4 | – | 30.9 | – |
| Gross profit | 164.0 | 228.0 | 231.5 | 207.8 | 200.6 | +22.3 | 201.9 | (11.4) | 232.9 | +0.6 | 258.7 | +24.5 |
| (% of Revenue) | 69.2 | 72.2 | 73.3 | 68.8 | 69.5 | – | 69.6 | – | 69.9 | – | 74.7 | – |
| Research and development | (41.4) | (42.9) | (44.9) | (52.2) | (40.9) | (1.2) | (45.7) | +6.5 | (48.6) | +8.2 | (52.4) | +0.4 |
| (% of Revenue) | 17.5 | 13.6 | 14.2 | 17.3 | 14.2 | – | 15.8 | – | 14.6 | – | 15.1 | – |
| Selling, general and administration | (22.6) | (27.3) | (27.8) | (32.4) | (23.2) | +2.7 | (28.4) | +4.0 | (27.9) | +0.4 | (36.9) | +13.9 |
| (% of Revenue) | 9.5 | 8.6 | 8.8 | 10.7 | 8.0 | – | 9.8 | – | 8.4 | – | 10.7 | – |
| Other operating income (expense) | (0.2) | 0.6 | 1.6 | 0.3 | 0.2 | – | 8.8 | 15times | 0.0 | – | (0.4) | – |
| Operating profit | 99.9 | 158.3 | 160.4 | 123.4 | 136.7 | +36.8 | 136.7 | (13.6) | 156.5 | (2.4) | 169.0 | +37.0 |
| (% of Revenue) | 42.2 | 50.1 | 50.8 | 40.8 | 47.4 | – | 47.1 | – | 47.0 | – | 48.8 | – |
| Financing costs | 0.0 | 0.0 | 0.0 | (0.0) | 0.0 | 0.0 | (0.1) | – | (0.1) | – | (0.1) | – |
| Other financial income (expense) | 0.0 | 0.5 | (1.6) | 2.1 | (0.8) | – | (0.6) | – | (0.4) | (75.0) | 1.0 | (52.4) |
| Profit before taxes | 99.9 | 158.8 | 158.8 | 125.5 | 135.8 | +35.9 | 136.0 | (14.4) | 156.1 | (1.7) | 169.9 | +35.4 |
| (% of Revenue) | 42.2 | 50.3 | 50.3 | 41.5 | 47.1 | – | 46.9 | – | 46.8 | – | 49.1 | – |
| Income taxes | (25.5) | (46.9) | (49.3) | (33.9) | (38.6) | +51.4 | (38.8) | (17.3) | (44.9) | (8.9) | (41.5) | +22.4 |
| Net income | 74.4 | 111.9 | 109.5 | 91.6 | 97.2 | +30.6 | 97.2 | (13.1) | 111.2 | +1.6 | 128.4 | +40.2 |
| (% of Revenue) | 31.4 | 35.4 | 34.7 | 30.3 | 33.7 | – | 33.5 | – | 33.4 | – | 37.1 | – |
| Attributable to | | | | | | | | | | | | |
| Chugai shareholders | 74.4 | 111.9 | 109.5 | 91.6 | 97.2 | +30.6 | 97.2 | (13.1) | 111.2 | +1.6 | 128.4 | +40.2 |
| Non-controlling interests | – | – | – | – | – | – | – | – | – | – | – | – |
| Earnings per share | | | | | | | | | | | | |
| Basic (yen) | 45.22 | 67.98 | 66.54 | 55.64 | 59.09 | +30.7 | 59.04 | (13.2) | 67.58 | +1.6 | 78.03 | +40.2 |
| Diluted (yen) | 45.21 | 67.97 | 66.54 | 55.64 | 59.08 | +30.7 | 59.03 | (13.2) | 67.58 | +1.6 | 78.02 | +40.2 |

Other financial income (expense) includes net amount of FX related gains/losses.

IFRS results (YTD)

(Billions of yen)

| | Actual | | | | Actual | | | | | | | |
|--|--------|---------|---------|---------|--------|------------|---------|------------|---------|------------|---------|------------|
| | FY2024 | | | | FY2025 | | | | | | | |
| | 1-3 | 1-6 | 1-9 | 1-12 | 1-3 | Change (%) | 1-6 | Change (%) | 1-9 | Change (%) | 1-12 | Change (%) |
| | YTD | YTD | YTD | YTD | YTD | | YTD | | YTD | | YTD | |
| Revenue | 236.9 | 552.9 | 868.5 | 1,170.6 | 288.5 | +21.8 | 578.5 | +4.6 | 911.6 | +5.0 | 1,257.9 | +7.5 |
| Sales | 204.5 | 485.5 | 750.3 | 997.9 | 259.7 | +27.0 | 511.4 | +5.3 | 794.6 | +5.9 | 1,077.8 | +8.0 |
| Domestic | 103.2 | 217.2 | 331.7 | 461.1 | 103.0 | (0.2) | 223.3 | +2.8 | 343.7 | +3.6 | 472.4 | +2.5 |
| Overseas | 101.3 | 268.4 | 418.7 | 536.8 | 156.7 | +54.7 | 288.1 | +7.3 | 450.9 | +7.7 | 605.4 | +12.8 |
| Other revenue | 32.5 | 67.3 | 118.2 | 172.7 | 28.7 | (11.7) | 67.0 | (0.4) | 117.1 | (0.9) | 180.1 | +4.3 |
| Royalty income and profit-sharing income | 21.0 | 54.8 | 94.5 | 147.4 | 25.3 | +20.5 | 62.3 | +13.7 | 112.3 | +18.8 | 172.7 | +17.2 |
| of which income from Roche | 20.4 | 53.7 | 92.6 | 144.7 | 24.5 | +20.1 | 59.9 | +11.5 | 107.3 | +15.9 | 163.3 | +12.9 |
| Other operating income | 11.5 | 12.5 | 23.8 | 25.3 | 3.4 | (70.4) | 4.7 | (62.4) | 4.7 | (80.3) | 7.5 | (70.4) |
| Cost of sales | (72.9) | (160.9) | (245.1) | (339.4) | (87.8) | +20.4 | (175.9) | +9.3 | (276.1) | +12.6 | (363.7) | +7.2 |
| (% of Sales) | 35.6 | 33.1 | 32.7 | 34.0 | 33.8 | – | 34.4 | – | 34.7 | – | 33.7 | – |
| Gross profit | 164.0 | 392.0 | 623.4 | 831.2 | 200.6 | +22.3 | 402.6 | +2.7 | 635.5 | +1.9 | 894.3 | +7.6 |
| (% of Revenue) | 69.2 | 70.9 | 71.8 | 71.0 | 69.5 | – | 69.6 | – | 69.7 | – | 71.1 | – |
| Research and development | (41.4) | (84.3) | (129.2) | (181.4) | (40.9) | (1.2) | (86.6) | +2.7 | (135.2) | +4.6 | (187.6) | +3.4 |
| (% of Revenue) | 17.5 | 15.2 | 14.9 | 15.5 | 14.2 | – | 15.0 | – | 14.8 | – | 14.9 | – |
| Selling, general and administration | (22.6) | (49.9) | (77.7) | (110.1) | (23.2) | +2.7 | (51.6) | +3.4 | (79.5) | +2.3 | (116.5) | +5.8 |
| (% of Revenue) | 9.5 | 9.0 | 8.9 | 9.4 | 8.0 | – | 8.9 | – | 8.7 | – | 9.3 | – |
| Other operating income (expense) | (0.2) | 0.4 | 2.1 | 2.3 | 0.2 | – | 9.0 | 23times | 9.0 | +328.6 | 8.6 | +273.9 |
| Operating profit | 99.9 | 258.2 | 418.6 | 542.0 | 136.7 | +36.8 | 273.3 | +5.8 | 429.8 | +2.7 | 598.8 | +10.5 |
| (% of Revenue) | 42.2 | 46.7 | 48.2 | 46.3 | 47.4 | – | 47.2 | – | 47.1 | – | 47.6 | – |
| Financing costs | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | (0.1) | – | (0.1) | – | (0.2) | – |
| Other financial income (expense) | 0.0 | 0.5 | (1.1) | 1.0 | (0.8) | – | (1.5) | – | (1.8) | +63.6 | (0.8) | – |
| Profit before taxes | 99.9 | 258.7 | 417.5 | 543.0 | 135.8 | +35.9 | 271.8 | +5.1 | 427.9 | +2.5 | 597.8 | +10.1 |
| (% of Revenue) | 42.2 | 46.8 | 48.1 | 46.4 | 47.1 | – | 47.0 | – | 46.9 | – | 47.5 | – |
| Income taxes | (25.5) | (72.4) | (121.8) | (155.7) | (38.6) | +51.4 | (77.4) | +6.9 | (122.3) | +0.4 | (163.8) | +5.2 |
| Net income | 74.4 | 186.3 | 295.8 | 387.3 | 97.2 | +30.6 | 194.4 | +4.3 | 305.6 | +3.3 | 434.0 | +12.1 |
| (% of Revenue) | 31.4 | 33.7 | 34.1 | 33.1 | 33.7 | – | 33.6 | – | 33.5 | – | 34.5 | – |
| Attributable to | | | | | | | | | | | | |
| Chugai shareholders | 74.4 | 186.3 | 295.8 | 387.3 | 97.2 | +30.6 | 194.4 | +4.3 | 305.6 | +3.3 | 434.0 | +12.1 |
| Non-controlling interests | – | – | – | – | – | – | – | – | – | – | – | – |
| Earnings per share | | | | | | | | | | | | |
| Basic (yen) | 45.22 | 113.20 | 179.75 | 235.39 | 59.09 | +30.7 | 118.13 | +4.4 | 185.70 | +3.3 | 263.73 | +12.0 |
| Diluted (yen) | 45.21 | 113.19 | 179.72 | 235.36 | 59.08 | +30.7 | 118.12 | +4.4 | 185.70 | +3.3 | 263.72 | +12.0 |

Other financial income (expense) includes net amount of FX related gains/losses.

Core results (QTD)

(Billions of yen)

| | Actual | | | | Actual | | | | | | | |
|--|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|--------|
| | FY2024 | | | | FY2025 | | | | | | | |
| | 1-3 | 4-6 | 7-9 | 10-12 | 1-3 | Change | 4-6 | Change | 7-9 | Change | 10-12 | Change |
| | QTD | QTD | QTD | QTD | QTD | (%) | QTD | (%) | QTD | (%) | QTD | (%) |
| Revenue | 236.9 | 315.9 | 315.7 | 302.1 | 288.5 | +21.8 | 290.0 | (8.2) | 333.2 | +5.5 | 346.3 | +14.6 |
| Sales | 204.5 | 281.1 | 264.8 | 247.6 | 259.7 | +27.0 | 251.7 | (10.5) | 283.1 | +6.9 | 283.2 | +14.4 |
| Domestic | 103.2 | 114.0 | 114.5 | 129.5 | 103.0 | (0.2) | 120.4 | +5.6 | 120.4 | +5.2 | 128.6 | (0.7) |
| Overseas | 101.3 | 167.1 | 150.3 | 118.1 | 156.7 | +54.7 | 131.4 | (21.4) | 162.8 | +8.3 | 154.6 | +30.9 |
| Other revenue | 32.5 | 34.9 | 50.9 | 54.5 | 28.7 | (11.7) | 38.3 | +9.7 | 50.0 | (1.8) | 63.1 | +15.8 |
| Royalty income and profit-sharing income | 21.0 | 33.8 | 39.6 | 53.0 | 25.3 | +20.5 | 37.0 | +9.5 | 50.0 | +26.3 | 60.3 | +13.8 |
| of which income from Roche | 20.4 | 33.4 | 38.9 | 52.1 | 24.5 | +20.1 | 35.5 | +6.3 | 47.3 | +21.6 | 56.0 | +7.5 |
| Other operating income | 11.5 | 1.0 | 11.2 | 1.5 | 3.4 | (70.4) | 1.3 | +30.0 | (0.0) | – | 2.7 | +80.0 |
| Cost of sales | (72.6) | (87.6) | (83.9) | (94.0) | (87.5) | +20.5 | (87.7) | +0.1 | (88.2) | +5.1 | (88.2) | (6.2) |
| (% of Sales) | 35.5 | 31.2 | 31.7 | 38.0 | 33.7 | – | 34.8 | – | 31.2 | – | 31.1 | – |
| Gross profit | 164.3 | 228.3 | 231.8 | 208.1 | 201.0 | +22.3 | 202.3 | (11.4) | 245.0 | +5.7 | 258.1 | +24.0 |
| (% of Revenue) | 69.4 | 72.3 | 73.4 | 68.9 | 69.7 | – | 69.8 | – | 73.5 | – | 74.5 | – |
| Research and development | (41.2) | (42.8) | (43.9) | (49.1) | (40.7) | (1.2) | (45.5) | +6.3 | (42.6) | (3.0) | (51.2) | +4.3 |
| (% of Revenue) | 17.4 | 13.5 | 13.9 | 16.3 | 14.1 | – | 15.7 | – | 12.8 | – | 14.8 | – |
| Selling, general and administration | (21.2) | (25.4) | (25.9) | (29.8) | (21.0) | (0.9) | (24.4) | (3.9) | (24.0) | (7.3) | (33.8) | 13.4 |
| (% of Revenue) | 8.9 | 8.0 | 8.2 | 9.9 | 7.3 | – | 8.4 | – | 7.2 | – | 9.8 | – |
| Other operating income (expense) | 0.2 | 0.6 | 1.6 | 0.3 | 0.3 | +50.0 | 0.1 | (83.3) | 0.0 | – | (0.4) | – |
| Operating profit | 102.1 | 160.7 | 163.7 | 129.5 | 139.5 | +36.6 | 132.5 | (17.5) | 178.5 | +9.0 | 172.7 | +33.4 |
| (% of Revenue) | 43.1 | 50.9 | 51.9 | 42.9 | 48.4 | – | 45.7 | – | 53.6 | – | 49.9 | – |
| Financing costs | 0.0 | 0.0 | 0.0 | (0.0) | 0.0 | 0.0 | (0.1) | – | (0.1) | – | (0.1) | – |
| Other financial income (expense) | 0.0 | 0.5 | (1.6) | 2.1 | (0.8) | – | (0.6) | – | (0.4) | (75.0) | 1.0 | (52.4) |
| Profit before taxes | 102.1 | 161.2 | 162.1 | 131.6 | 138.7 | +35.8 | 131.8 | (18.2) | 178.1 | +9.9 | 173.6 | +31.9 |
| (% of Revenue) | 43.1 | 51.0 | 51.3 | 43.6 | 48.1 | – | 45.4 | – | 53.5 | – | 50.1 | – |
| Income taxes | (26.2) | (47.7) | (50.3) | (35.8) | (39.5) | +50.8 | (37.6) | (21.2) | (51.6) | +2.6 | (42.6) | +19.0 |
| Net income | 76.0 | 113.5 | 111.8 | 95.8 | 99.2 | +30.5 | 94.3 | (16.9) | 126.5 | +13.1 | 131.0 | +36.7 |
| (% of Revenue) | 32.1 | 35.9 | 35.4 | 31.7 | 34.4 | – | 32.5 | – | 38.0 | – | 37.8 | – |
| Attributable to | | | | | | | | | | | | |
| Chugai shareholders | 76.0 | 113.5 | 111.8 | 95.8 | 99.2 | +30.5 | 94.3 | (16.9) | 126.5 | +13.1 | 131.0 | +36.7 |
| Non-controlling interests | – | – | – | – | – | – | – | – | – | – | – | – |
| Core earnings per share (diluted) (yen) | 46.16 | 68.99 | 67.93 | 58.22 | 60.30 | +30.6 | 57.27 | (17.0) | 76.87 | +13.2 | 79.58 | +36.7 |

Please see page 1 “Reconciliation of IFRS results to Core results” for the detail of the adjustments.

Core earnings per share (diluted) (yen) : Net income attributable to Chugai shareholders / Weighted average number of shares in issue used to calculate diluted earnings per share.

Other financial income (expense) includes net amount of FX related gains/losses.

Core results (YTD)

(Billions of yen)

| | Actual | | | | Actual | | | | | | | | Forecast (Jan 29th announced) | |
|--|--------|---------|---------|---------|--------|---------------|---------|---------------|---------|---------------|---------|---------------|-------------------------------------|---------------|
| | FY2024 | | | | FY2025 | | | | | | | | FY2026 | |
| | 1-3 | 1-6 | 1-9 | 1-12 | 1-3 | Change (%) | 1-6 | Change (%) | 1-9 | Change (%) | 1-12 | Change (%) | 1-12 | Change (%) |
| | YTD | YTD | YTD | YTD | YTD | | YTD | | YTD | | YTD | | YTD | |
| Revenue | 236.9 | 552.9 | 868.5 | 1,170.6 | 288.5 | +21.8 | 578.5 | +4.6 | 911.6 | +5.0 | 1,257.9 | +7.5 | 1,345.0 | +6.9 |
| Sales | 204.5 | 485.5 | 750.3 | 997.9 | 259.7 | +27.0 | 511.4 | +5.3 | 794.6 | +5.9 | 1,077.8 | +8.0 | 1,100.0 | +2.1 |
| Domestic | 103.2 | 217.2 | 331.7 | 461.1 | 103.0 | (0.2) | 223.3 | +2.8 | 343.7 | +3.6 | 472.4 | +2.5 | 498.0 | +5.4 |
| Overseas | 101.3 | 268.4 | 418.7 | 536.8 | 156.7 | +54.7 | 288.1 | +7.3 | 450.9 | +7.7 | 605.4 | +12.8 | 602.0 | (0.6) |
| Other revenue | 32.5 | 67.3 | 118.2 | 172.7 | 28.7 | (11.7) | 67.0 | (0.4) | 117.1 | (0.9) | 180.1 | +4.3 | 245.0 | +36.0 |
| Royalty income and profit-sharing income | 21.0 | 54.8 | 94.5 | 147.4 | 25.3 | +20.5 | 62.3 | +13.7 | 112.3 | +18.8 | 172.7 | +17.2 | 217.2 | +25.8 |
| of which income from Roche | 20.4 | 53.7 | 92.6 | 144.7 | 24.5 | +20.1 | 59.9 | +11.5 | 107.3 | +15.9 | 163.3 | +12.9 | 178.5 | +9.3 |
| Other operating income | 11.5 | 12.5 | 23.8 | 25.3 | 3.4 | (70.4) | 4.7 | (62.4) | 4.7 | (80.3) | 7.5 | (70.4) | 27.8 | +270.7 |
| Cost of sales | (72.6) | (160.2) | (244.1) | (338.1) | (87.5) | +20.5 | (175.2) | +9.4 | (263.3) | +7.9 | (351.5) | +4.0 | (383.5) | +9.1 |
| (% of Sales) | 35.5 | 33.0 | 32.5 | 33.9 | 33.7 | – | 34.3 | – | 33.1 | – | 32.6 | – | 34.9 | – |
| Gross profit | 164.3 | 392.6 | 624.4 | 832.5 | 201.0 | +22.3 | 403.3 | +2.7 | 648.3 | +3.8 | 906.5 | +8.9 | 961.5 | +6.1 |
| (% of Revenue) | 69.4 | 71.0 | 71.9 | 71.1 | 69.7 | – | 69.7 | – | 71.1 | – | 72.1 | – | 71.5 | – |
| Research and development | (41.2) | (84.0) | (127.9) | (176.9) | (40.7) | (1.2) | (86.3) | +2.7 | (128.8) | +0.7 | (180.1) | +1.8 | (190.0) | +5.5 |
| (% of Revenue) | 17.4 | 15.2 | 14.7 | 15.1 | 14.1 | – | 14.9 | – | 14.1 | – | 14.3 | – | 14.1 | – |
| Selling, general and administration | (21.2) | (46.6) | (72.5) | (102.2) | (21.0) | (0.9) | (45.4) | (2.6) | (69.4) | (4.3) | (103.2) | +1.0 | (102.0) | (1.2) |
| (% of Revenue) | 8.9 | 8.4 | 8.3 | 8.7 | 7.3 | – | 7.8 | – | 7.6 | – | 8.2 | – | 7.6 | – |
| Other operating income (expense) | 0.2 | 0.8 | 2.4 | 2.7 | 0.3 | +50.0 | 0.4 | (50.0) | 0.4 | (83.3) | 0.0 | – | 0.5 | – |
| Operating profit | 102.1 | 262.8 | 426.6 | 556.1 | 139.5 | +36.6 | 272.0 | +3.5 | 450.5 | +5.6 | 623.2 | +12.1 | 670.0 | +7.5 |
| (% of Revenue) | 43.1 | 47.5 | 49.1 | 47.5 | 48.4 | – | 47.0 | – | 49.4 | – | 49.5 | – | 49.8 | – |
| Financing costs | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | (0.1) | – | (0.1) | – | (0.2) | – | – | – |
| Other financial income (expense) | 0.0 | 0.5 | (1.1) | 1.0 | (0.8) | – | (1.5) | – | (1.8) | +63.6 | (0.8) | – | – | – |
| Profit before taxes | 102.1 | 263.3 | 425.5 | 557.1 | 138.7 | +35.8 | 270.5 | +2.7 | 448.6 | +5.4 | 622.2 | +11.7 | – | – |
| (% of Revenue) | 43.1 | 47.6 | 49.0 | 47.6 | 48.1 | – | 46.8 | – | 49.2 | – | 49.5 | – | – | – |
| Income taxes | (26.2) | (73.8) | (124.2) | (160.0) | (39.5) | +50.8 | (77.0) | +4.3 | (128.6) | +3.5 | (171.2) | +7.0 | – | – |
| Net income | 76.0 | 189.5 | 301.3 | 397.1 | 99.2 | +30.5 | 193.5 | +2.1 | 320.0 | +6.2 | 451.0 | +13.6 | 485.0 | +7.5 |
| (% of Revenue) | 32.1 | 34.3 | 34.7 | 33.9 | 34.4 | – | 33.4 | – | 35.1 | – | 35.9 | – | 36.1 | – |
| Attributable to | | | | | | | | | | | | | | |
| Chugai shareholders | 76.0 | 189.5 | 301.3 | 397.1 | 99.2 | +30.5 | 193.5 | +2.1 | 320.0 | +6.2 | 451.0 | +13.6 | – | – |
| Non-controlling interests | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Weighted average number of shares in issue used to calculate diluted earnings per share (Millions of shares) | 1,646 | 1,646 | 1,646 | 1,646 | 1,646 | 0.0 | 1,646 | 0.0 | 1,646 | 0.0 | 1,646 | 0.0 | – | – |
| Core earnings per share (diluted) (yen) | 46.16 | 115.15 | 183.09 | 241.31 | 60.30 | +30.6 | 117.57 | +2.1 | 194.44 | +6.2 | 274.02 | +13.6 | 295.00 | +7.7 |
| Core payout ratio (%) | | | | 40.6 | | | | | | | | 99.3 | 44.7 | – |
| Dividend per share (Full year) (yen) | | | | 98 | | | | | | | | 272 | 132 | – |
| Dividend per share (Year end) (yen) | | | | 57 | | | | | | | | 147 | 66 | – |
| Dividend per share (Half year) (yen) | | | | 41 | | | | | | | | 125 | 66 | – |

Please see page 1 “Reconciliation of IFRS results to Core results” for the detail of the adjustments.

Core earnings per share (diluted) (yen) : Net income attributable to Chugai shareholders / Weighted average number of shares in issue used to calculate diluted earnings per share.

Other financial income (expense) includes net amount of FX related gains/losses.

The annual dividend per share for the year ended December 31, 2025 consists of a regular dividend of 122 yen (half-year: 50 yen, year-end: 72 yen) and a special dividend for the company's 100th Anniversary of 150 yen (half-year: 75 yen, year-end: 75 yen).

Core statements of revenue (QTD)

(Billions of yen)

| | Actual | | | | Actual | | | | | | | |
|---------------------|--------|-------|-------|-------|--------|---------|-------|--------|-------|--------|-------|--------|
| | FY2024 | | | | FY2025 | | | | | | | |
| | 1-3 | 4-6 | 7-9 | 10-12 | 1-3 | Change | 4-6 | Change | 7-9 | Change | 10-12 | Change |
| | QTD | QTD | QTD | QTD | QTD | (%) | QTD | (%) | QTD | (%) | QTD | (%) |
| Sales | 204.5 | 281.1 | 264.8 | 247.6 | 259.7 | +27.0 | 251.7 | (10.5) | 283.1 | +6.9 | 283.2 | +14.4 |
| Domestic | 103.2 | 114.0 | 114.5 | 129.5 | 103.0 | (0.2) | 120.4 | +5.6 | 120.4 | +5.2 | 128.6 | (0.7) |
| Oncology | 56.1 | 62.6 | 61.6 | 67.4 | 53.1 | (5.3) | 63.5 | +1.4 | 64.1 | +4.1 | 65.8 | (2.4) |
| Tecentriq | 14.5 | 16.6 | 16.3 | 18.0 | 13.8 | (4.8) | 16.1 | (3.0) | 16.1 | (1.2) | 16.8 | (6.7) |
| Polivy | 7.4 | 8.3 | 8.8 | 9.7 | 7.5 | +1.4 | 9.4 | +13.3 | 10.0 | +13.6 | 10.2 | +5.2 |
| Alecensa | 6.6 | 8.2 | 7.5 | 8.6 | 7.5 | +13.6 | 8.2 | 0.0 | 8.6 | +14.7 | 9.2 | +7.0 |
| Phesgo | 3.2 | 5.4 | 6.5 | 8.4 | 6.8 | +112.5 | 8.6 | +59.3 | 9.1 | +40.0 | 9.4 | +11.9 |
| Avastin | 8.7 | 8.7 | 8.2 | 8.2 | 6.1 | (29.9) | 6.9 | (20.7) | 6.6 | (19.5) | 6.5 | (20.7) |
| Kadcyla | 3.6 | 4.3 | 4.3 | 4.7 | 3.5 | (2.8) | 4.3 | 0.0 | 4.2 | (2.3) | 4.3 | (8.5) |
| Perjeta | 6.1 | 5.2 | 4.4 | 4.3 | 3.0 | (50.8) | 3.4 | (34.6) | 3.2 | (27.3) | 3.0 | (30.2) |
| Lunsumio | – | – | – | – | 0.0 | – | 0.9 | – | 1.2 | – | 1.1 | – |
| Herceptin | 0.7 | 0.6 | 0.5 | 0.5 | 0.3 | (57.1) | 0.4 | (33.3) | 0.3 | (40.0) | 0.3 | (40.0) |
| Foundation Medicine | 1.8 | 1.8 | 2.2 | 1.9 | 2.0 | +11.1 | 1.9 | 5.6 | 2.2 | 0.0 | 1.9 | 0.0 |
| Other products | 3.4 | 3.5 | 3.0 | 3.1 | 2.6 | (23.5) | 3.4 | (2.9) | 2.6 | (13.3) | 3.1 | 0.0 |
| Specialty | 47.0 | 51.3 | 52.9 | 62.1 | 49.9 | +6.2 | 56.8 | +10.7 | 56.3 | +6.4 | 62.8 | +1.1 |
| Hemlibra | 12.5 | 14.9 | 14.1 | 17.5 | 12.6 | +0.8 | 16.4 | +10.1 | 15.7 | +11.3 | 18.0 | +2.9 |
| Actemra | 10.2 | 12.2 | 12.4 | 13.1 | 10.9 | +6.9 | 12.9 | +5.7 | 13.0 | +4.8 | 13.8 | +5.3 |
| Enspryng | 5.8 | 5.8 | 6.2 | 6.9 | 6.1 | +5.2 | 7.1 | +22.4 | 7.6 | +22.6 | 8.3 | +20.3 |
| Vabysmo | 4.0 | 5.2 | 5.6 | 6.7 | 5.4 | +35.0 | 6.6 | +26.9 | 6.6 | +17.9 | 7.7 | +14.9 |
| Evrysdi | 3.4 | 4.1 | 3.8 | 4.6 | 3.4 | 0.0 | 4.5 | +9.8 | 4.1 | +7.9 | 4.2 | (8.7) |
| CellCept | 1.5 | 1.6 | 1.6 | 2.1 | 2.0 | +33.3 | 2.2 | +37.5 | 1.8 | +12.5 | 2.0 | (4.8) |
| Mircera | 1.5 | 1.7 | 1.6 | 1.7 | 1.2 | (20.0) | 1.3 | (23.5) | 1.3 | (18.8) | 1.3 | (23.5) |
| PiaSky | – | 0.4 | 0.9 | 1.3 | 1.3 | – | 1.7 | +325.0 | 1.8 | +100.0 | 2.0 | +53.8 |
| Other products | 8.1 | 5.6 | 6.7 | 8.2 | 7.0 | (13.6) | 4.1 | (26.8) | 4.5 | (32.8) | 5.4 | (34.1) |
| Tamiflu | 1.3 | 0.1 | 0.6 | 2.6 | 2.3 | +76.9 | 0.0 | – | 0.0 | – | 0.2 | (92.3) |
| Overseas | 101.3 | 167.1 | 150.3 | 118.1 | 156.7 | +54.7 | 131.4 | (21.4) | 162.8 | +8.3 | 154.6 | +30.9 |
| Hemlibra | 57.8 | 102.8 | 92.9 | 54.2 | 86.2 | +49.1 | 64.5 | (37.3) | 103.9 | +11.8 | 89.8 | +65.7 |
| To Roche | 56.9 | 101.9 | 91.7 | 52.9 | 85.0 | +49.4 | 63.3 | (37.9) | 102.8 | +12.1 | 88.3 | +66.9 |
| Actemra | 23.4 | 38.2 | 32.0 | 38.3 | 42.5 | +81.6 | 44.4 | +16.2 | 32.1 | +0.3 | 39.1 | +2.1 |
| To Roche | 22.1 | 37.0 | 30.7 | 37.0 | 41.3 | +86.9 | 43.1 | +16.5 | 30.8 | +0.3 | 37.6 | +1.6 |
| Alecensa | 14.0 | 16.5 | 16.1 | 16.1 | 17.4 | +24.3 | 11.7 | (29.1) | 16.9 | +5.0 | 13.2 | (18.0) |
| To Roche | 13.2 | 15.8 | 15.4 | 15.4 | 16.6 | +25.8 | 11.0 | (30.4) | 16.1 | +4.5 | 12.4 | (19.5) |
| Enspryng | 2.1 | 2.9 | 3.7 | 5.0 | 3.1 | +47.6 | 2.9 | 0.0 | 2.6 | (29.7) | 2.6 | (48.0) |
| To Roche | 2.1 | 2.9 | 3.6 | 4.9 | 3.0 | +42.9 | 2.8 | (3.4) | 2.5 | (30.6) | 2.5 | (49.0) |
| Sigmart | 1.7 | 2.5 | 1.9 | 1.9 | 2.2 | +29.4 | 2.3 | (8.0) | 2.3 | +21.1 | 1.7 | (10.5) |
| Neutrogin | 2.1 | 2.5 | 2.1 | 1.9 | 2.4 | +14.3 | 2.2 | (12.0) | 2.1 | 0.0 | 2.2 | +15.8 |
| Other products | 0.2 | 1.5 | 1.5 | 0.7 | 2.9 | 15times | 3.3 | +120.0 | 2.9 | +93.3 | 5.8 | +728.6 |
| Other revenue | 32.5 | 34.9 | 50.9 | 54.5 | 28.7 | (11.7) | 38.3 | +9.7 | 50.0 | (1.8) | 63.1 | +15.8 |
| Revenue | 236.9 | 315.9 | 315.7 | 302.1 | 288.5 | +21.8 | 290.0 | (8.2) | 333.2 | +5.5 | 346.3 | +14.6 |
| Domestic | 103.5 | 114.6 | 114.9 | 130.9 | 103.4 | (0.1) | 121.2 | +5.8 | 120.6 | +5.0 | 128.8 | (1.6) |
| Overseas | 133.5 | 201.3 | 200.8 | 171.2 | 185.1 | +38.7 | 168.9 | (16.1) | 212.7 | +5.9 | 217.5 | +27.0 |

Core statements of revenue (YTD)

(Billions of yen)

| | Actual | | | | Actual | | | | | | | | Forecast (Jan 29th announced) | |
|---------------------|--------|-------|-------|---------|--------|---------------|-------|---------------|-------|---------------|---------|---------------|-------------------------------------|---------------|
| | FY2024 | | | | FY2025 | | | | | | | | FY2026 | |
| | 1-3 | 1-6 | 1-9 | 1-12 | 1-3 | Change (%) | 1-6 | Change (%) | 1-9 | Change (%) | 1-12 | Change (%) | 1-12 | Change (%) |
| | YTD | YTD | YTD | YTD | YTD | | YTD | | YTD | | YTD | | YTD | |
| Sales | 204.5 | 485.5 | 750.3 | 997.9 | 259.7 | +27.0 | 511.4 | +5.3 | 794.6 | +5.9 | 1,077.8 | +8.0 | 1,100.0 | +2.1 |
| Domestic | 103.2 | 217.2 | 331.7 | 461.1 | 103.0 | (0.2) | 223.3 | +2.8 | 343.7 | +3.6 | 472.4 | +2.5 | 498.0 | +5.4 |
| Oncology | 56.1 | 118.8 | 180.3 | 247.7 | 53.1 | (5.3) | 116.6 | (1.9) | 180.7 | +0.2 | 246.5 | (0.5) | 259.2 | +5.2 |
| Tecentriq | 14.5 | 31.1 | 47.4 | 65.4 | 13.8 | (4.8) | 29.9 | (3.9) | 46.0 | (3.0) | 62.8 | (4.0) | 61.1 | (2.7) |
| Polivy | 7.4 | 15.7 | 24.5 | 34.1 | 7.5 | +1.4 | 17.0 | +8.3 | 27.0 | +10.2 | 37.2 | +9.1 | 42.5 | +14.2 |
| Alecensa | 6.6 | 14.9 | 22.4 | 31.0 | 7.5 | +13.6 | 15.8 | +6.0 | 24.3 | +8.5 | 33.5 | +8.1 | 32.8 | (2.1) |
| Phesgo | 3.2 | 8.6 | 15.0 | 23.5 | 6.8 | +112.5 | 15.4 | +79.1 | 24.5 | +63.3 | 33.9 | +44.3 | 35.1 | +3.5 |
| Avastin | 8.7 | 17.4 | 25.6 | 33.8 | 6.1 | (29.9) | 13.0 | (25.3) | 19.6 | (23.4) | 26.1 | (22.8) | 13.7 | (47.5) |
| Kadcyla | 3.6 | 7.9 | 12.2 | 16.8 | 3.5 | (2.8) | 7.8 | (1.3) | 11.9 | (2.5) | 16.3 | (3.0) | 16.5 | +1.2 |
| Perjeta | 6.1 | 11.3 | 15.7 | 20.0 | 3.0 | (50.8) | 6.3 | (44.2) | 9.6 | (38.9) | 12.5 | (37.5) | 11.1 | (11.2) |
| Lunsumio | – | – | – | – | 0.0 | – | 1.0 | – | 2.2 | – | 3.3 | – | 28.4 | +760.6 |
| Herceptin | 0.7 | 1.4 | 1.9 | 2.4 | 0.3 | (57.1) | 0.7 | (50.0) | 1.0 | (47.4) | 1.3 | (45.8) | – | – |
| Foundation Medicine | 1.8 | 3.6 | 5.8 | 7.6 | 2.0 | +11.1 | 3.9 | +8.3 | 6.0 | +3.4 | 7.9 | +3.9 | 7.8 | (1.3) |
| Other products | 3.4 | 7.0 | 9.9 | 13.1 | 2.6 | (23.5) | 6.0 | (14.3) | 8.5 | (14.1) | 11.7 | (10.7) | 10.1 | (22.3) |
| Specialty | 47.0 | 98.4 | 151.3 | 213.4 | 49.9 | +6.2 | 106.7 | +8.4 | 163.0 | +7.7 | 225.8 | +5.8 | 238.8 | +5.8 |
| Hemlibra | 12.5 | 27.4 | 41.5 | 59.0 | 12.6 | +0.8 | 29.1 | +6.2 | 44.7 | +7.7 | 62.7 | +6.3 | 66.6 | +6.2 |
| Actemra | 10.2 | 22.4 | 34.8 | 48.0 | 10.9 | +6.9 | 23.8 | +6.3 | 36.7 | +5.5 | 50.5 | +5.2 | 46.2 | (8.5) |
| Enspryng | 5.8 | 11.6 | 17.8 | 24.7 | 6.1 | +5.2 | 13.3 | +14.7 | 20.9 | +17.4 | 29.2 | +18.2 | 31.9 | +9.2 |
| Vabysmo | 4.0 | 9.1 | 14.7 | 21.5 | 5.4 | +35.0 | 12.0 | +31.9 | 18.5 | +25.9 | 26.2 | +21.9 | 30.1 | +14.9 |
| Evrysdi | 3.4 | 7.5 | 11.3 | 15.9 | 3.4 | 0.0 | 7.9 | +5.3 | 12.0 | +6.2 | 16.2 | +1.9 | 15.2 | (6.2) |
| CellCept | 1.5 | 3.1 | 4.7 | 6.8 | 2.0 | +33.3 | 4.2 | +35.5 | 6.0 | +27.7 | 8.0 | +17.6 | 7.1 | (11.3) |
| Mircera | 1.5 | 3.2 | 4.8 | 6.5 | 1.2 | (20.0) | 2.4 | (25.0) | 3.7 | (22.9) | 5.1 | (21.5) | – | – |
| PiaSky | – | 0.4 | 1.3 | 2.6 | 1.3 | – | 3.0 | +650.0 | 4.8 | +269.2 | 6.9 | +165.4 | 8.3 | +20.3 |
| Other products | 8.1 | 13.6 | 20.3 | 28.5 | 7.0 | (13.6) | 11.1 | (18.4) | 15.6 | (23.2) | 21.0 | (26.3) | 33.3 | +27.6 |
| Tamiflu | 1.3 | 1.3 | 2.0 | 4.5 | 2.3 | +76.9 | 2.3 | +76.9 | 2.3 | +15.0 | 2.5 | (44.4) | 2.7 | +8.0 |
| Overseas | 101.3 | 268.4 | 418.7 | 536.8 | 156.7 | +54.7 | 288.1 | +7.3 | 450.9 | +7.7 | 605.4 | +12.8 | 602.0 | (0.6) |
| Hemlibra | 57.8 | 160.6 | 253.5 | 307.7 | 86.2 | +49.1 | 150.7 | (6.2) | 254.6 | +0.4 | 344.5 | +12.0 | 354.0 | +2.8 |
| To Roche | 56.9 | 158.8 | 250.6 | 303.5 | 85.0 | +49.4 | 148.3 | (6.6) | 251.0 | +0.2 | 339.3 | +11.8 | 347.2 | +2.3 |
| Actemra | 23.4 | 61.6 | 93.6 | 131.9 | 42.5 | +81.6 | 86.9 | +41.1 | 119.0 | +27.1 | 158.2 | +19.9 | 136.3 | (13.8) |
| To Roche | 22.1 | 59.1 | 89.8 | 126.8 | 41.3 | +86.9 | 84.5 | +43.0 | 115.2 | +28.3 | 152.9 | +20.6 | 130.8 | (14.5) |
| Alecensa | 14.0 | 30.5 | 46.7 | 62.8 | 17.4 | +24.3 | 29.1 | (4.6) | 46.0 | (1.5) | 59.2 | (5.7) | 60.4 | +2.0 |
| To Roche | 13.2 | 29.0 | 44.4 | 59.7 | 16.6 | +25.8 | 27.5 | (5.2) | 43.6 | (1.8) | 56.0 | (6.2) | 57.1 | +2.0 |
| Enspryng | 2.1 | 5.1 | 8.8 | 13.8 | 3.1 | +47.6 | 6.1 | +19.6 | 8.6 | (2.3) | 11.3 | (18.1) | 9.2 | (18.6) |
| To Roche | 2.1 | 4.9 | 8.5 | 13.5 | 3.0 | +42.9 | 5.9 | +20.4 | 8.4 | (1.2) | 10.9 | (19.3) | 8.6 | (21.1) |
| Sigmart | 1.7 | 4.2 | 6.1 | 8.0 | 2.2 | +29.4 | 4.5 | +7.1 | 6.7 | +9.8 | 8.5 | +6.3 | 2.4 | (71.8) |
| Neutrogen | 2.1 | 4.6 | 6.7 | 8.6 | 2.4 | +14.3 | 4.6 | 0.0 | 6.7 | 0.0 | 8.9 | +3.5 | 7.0 | (21.3) |
| Other products | 0.2 | 1.7 | 3.2 | 3.9 | 2.9 | 15times | 6.3 | +270.6 | 9.2 | +187.5 | 15.0 | +284.6 | 32.6 | +117.3 |
| Other revenue | 32.5 | 67.3 | 118.2 | 172.7 | 28.7 | (11.7) | 67.0 | (0.4) | 117.1 | (0.9) | 180.1 | +4.3 | 245.0 | +36.0 |
| Revenue | 236.9 | 552.9 | 868.5 | 1,170.6 | 288.5 | +21.8 | 578.5 | +4.6 | 911.6 | +5.0 | 1,257.9 | +7.5 | 1,345.0 | +6.9 |
| Domestic | 103.5 | 218.1 | 333.0 | 463.9 | 103.4 | (0.1) | 224.4 | +2.9 | 345.0 | +3.6 | 473.8 | +2.1 | 500.5 | +5.6 |
| Overseas | 133.5 | 334.8 | 535.5 | 706.7 | 185.1 | +38.7 | 354.0 | +5.7 | 566.7 | +5.8 | 784.1 | +11.0 | 844.5 | +7.7 |

* "Herceptin" and "Mircera" are included in "Other products" in FY2026 forecast.

Also, "Herceptin" and "Mircera" are added to "Other products" in FY2025 actual for the percentage change calculation of "Other products" in FY2026 forecast.

Financial position

(Billions of yen)

| | Actual | | | | Actual | | | | | | | | | | |
|----------------------------------|---------|---------|---------|---------|---------|-------------------|-------------------|---------|-------------------|-------------------|---------|-------------------|-------------------|---------|-------------------|
| | FY2024 | | | | FY2025 | | | | | | | | | | |
| | Mar. 31 | Jun. 30 | Sep. 30 | Dec. 31 | Mar. 31 | vs. Mar. 31, 2024 | vs. Dec. 31, 2024 | Jun. 30 | vs. Jun. 30, 2024 | vs. Dec. 31, 2024 | Sep. 30 | vs. Sep. 30, 2024 | vs. Dec. 31, 2024 | Dec. 31 | vs. Dec. 31, 2024 |
| Trade accounts receivable | 209.4 | 296.9 | 266.2 | 258.4 | 252.1 | 42.7 | (6.3) | 261.1 | (35.8) | 2.7 | 287.2 | 21.0 | 28.8 | 317.5 | 59.1 |
| Inventories | 276.7 | 265.7 | 273.2 | 240.1 | 233.1 | (43.6) | (7.0) | 235.5 | (30.2) | (4.6) | 246.3 | (26.9) | 6.2 | 276.8 | 36.7 |
| Trade accounts payable | (40.4) | (40.4) | (44.7) | (16.1) | (22.0) | 18.4 | (5.9) | (43.1) | (2.7) | (27.0) | (45.2) | (0.5) | (29.1) | (89.2) | (73.1) |
| Other net working capital | (69.5) | (24.9) | (22.2) | (33.6) | (56.2) | 13.3 | (22.6) | (11.9) | 13.0 | 21.7 | (19.6) | 2.6 | 14.0 | 21.9 | 55.5 |
| Net working capital | 376.1 | 497.3 | 472.5 | 448.7 | 407.0 | 30.9 | (41.7) | 441.7 | (55.6) | (7.0) | 468.7 | (3.8) | 20.0 | 527.0 | 78.3 |
| Property, plant and equipment | 416.3 | 420.3 | 426.3 | 433.1 | 448.5 | 32.2 | 15.4 | 456.8 | 36.5 | 23.7 | 449.6 | 23.3 | 16.5 | 456.6 | 23.5 |
| Right-of-use assets | 10.1 | 9.9 | 9.4 | 8.4 | 15.1 | 5.0 | 6.7 | 14.6 | 4.7 | 6.2 | 13.5 | 4.1 | 5.1 | 22.9 | 14.5 |
| Intangible assets | 19.6 | 20.4 | 20.8 | 17.9 | 17.3 | (2.3) | (0.6) | 33.3 | 12.9 | 15.4 | 34.2 | 13.4 | 16.3 | 54.5 | 36.6 |
| Other long-term assets – net | 40.6 | 42.1 | 42.5 | 39.5 | 40.8 | 0.2 | 1.3 | 45.3 | 3.2 | 5.8 | 45.0 | 2.5 | 5.5 | 49.3 | 9.8 |
| Long-term net operating assets | 486.6 | 492.6 | 499.0 | 498.9 | 521.7 | 35.1 | 22.8 | 549.9 | 57.3 | 51.0 | 542.3 | 43.3 | 43.4 | 583.3 | 84.4 |
| Net operating assets | 862.7 | 989.9 | 971.4 | 947.6 | 928.7 | 66.0 | (18.9) | 991.5 | 1.6 | 43.9 | 1,011.0 | 39.6 | 63.4 | 1,110.3 | 162.7 |
| Debt | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |
| Marketable securities | 301.7 | 421.9 | 441.4 | 456.1 | 521.1 | 219.4 | 65.0 | 530.5 | 108.6 | 74.4 | 426.0 | (15.4) | (30.1) | 553.1 | 97.0 |
| Cash and cash equivalents | 462.9 | 393.8 | 404.0 | 540.2 | 423.4 | (39.5) | (116.8) | 497.1 | 103.3 | (43.1) | 456.4 | 52.4 | (83.8) | 426.6 | (113.6) |
| Net cash | 764.6 | 815.7 | 845.3 | 996.3 | 944.6 | 180.0 | (51.7) | 1,027.6 | 211.9 | 31.3 | 882.4 | 37.1 | (113.9) | 979.7 | (16.6) |
| Other non-operating assets – net | 14.8 | (53.9) | (15.4) | (42.5) | 33.9 | 19.1 | 76.4 | (34.0) | 19.9 | 8.5 | (3.3) | 12.1 | 39.2 | (64.3) | (21.8) |
| Net non-operating assets | 779.4 | 761.8 | 829.9 | 953.9 | 978.5 | 199.1 | 24.6 | 993.6 | 231.8 | 39.7 | 879.2 | 49.3 | (74.7) | 915.4 | (38.5) |
| Total net assets | 1,642.0 | 1,751.7 | 1,801.4 | 1,901.5 | 1,907.2 | 265.2 | 5.7 | 1,985.1 | 233.4 | 83.6 | 1,890.1 | 88.7 | (11.4) | 2,025.7 | 124.2 |
| Total net assets | | | | | | | | | | | | | | | |
| Total assets | 1,897.8 | 2,060.2 | 2,069.7 | 2,208.4 | 2,139.5 | 241.7 | (68.9) | 2,278.3 | 218.1 | 69.9 | 2,183.6 | 113.9 | (24.8) | 2,468.6 | 260.2 |
| Total liabilities | (255.7) | (308.5) | (268.4) | (306.9) | (232.3) | 23.4 | 74.6 | (293.2) | 15.3 | 13.7 | (293.5) | (25.1) | 13.4 | (442.9) | (136.0) |
| Attributable to | | | | | | | | | | | | | | | |
| Chugai shareholders | 1,642.0 | 1,751.7 | 1,801.4 | 1,901.5 | 1,907.2 | 265.2 | 5.7 | 1,985.1 | 233.4 | 83.6 | 1,890.1 | 88.7 | (11.4) | 2,025.7 | 124.2 |
| Non-controlling interests | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – |

Trade accounts receivable: trade receivable and notes receivable

Trade accounts payable: trade payable and notes payable

Other net working capital: accrued receivable (other receivable), accrued payable (other payable), accrued expenses (other current liabilities) etc.

Other long-term assets-net: long-term prepaid expenses, long-term provisions etc.

Other non-operating assets-net: deferred income tax assets, current income tax liabilities etc.

Net operating assets (NOA) and Net assets:

The consolidated balance sheet has been prepared in accordance with International Accounting Standards (IAS) No. 1, “Presentation of Financial Statements.” On the other hand, Net operating assets (NOA) and Net assets are a reconfiguration of the consolidated balance sheet as internal indicators and are identical to the indicators disclosed by Roche. Furthermore, no items from Net operating assets (NOA) and Net assets of IFRS have been excluded, as the Core results concept only applies to the income statement.

Net operating assets (NOA):

Net operating assets allow for an assessment of the Group’s operating performance of the business independently from financing and tax activities. Net operating assets are calculated as net working capital, long-term net operating assets that includes property, plant and equipment, right-of-use assets, intangible assets etc. minus provisions.

Cash flows

(Billions of yen)

| | Actual FY2024 | | | | Actual FY2025 | | | |
|--|------------------|--------|---------|---------|------------------|---------|---------|---------|
| | 1-3 | 1-6 | 1-9 | 1-12 | 1-3 | 1-6 | 1-9 | 1-12 |
| | YTD | YTD | YTD | YTD | YTD | YTD | YTD | YTD |
| Operating profit – IFRS basis | 99.9 | 258.2 | 418.6 | 542.0 | 136.7 | 273.3 | 429.8 | 598.8 |
| Depreciation and impairment of property, plant and equipment | 6.1 | 11.9 | 17.9 | 25.8 | 6.1 | 12.3 | 30.2 | 35.8 |
| Depreciation and impairment of right-of-use assets | 1.3 | 2.6 | 3.9 | 5.3 | 1.4 | 2.9 | 4.4 | 6.0 |
| Amortization and impairment of intangible assets | 0.6 | 1.2 | 2.8 | 6.4 | 0.5 | 0.9 | 1.3 | 3.3 |
| Other cash adjustment on operating profit | 0.3 | 1.2 | 1.2 | 5.3 | 1.5 | 0.4 | 7.1 | 7.6 |
| Operating profit, net of operating cash adjustments | 108.2 | 275.1 | 444.5 | 584.8 | 146.2 | 289.8 | 472.9 | 651.5 |
| (Increase) decrease in trade accounts receivable | 43.6 | (43.4) | (13.6) | (5.3) | 6.0 | (2.6) | (28.6) | (58.5) |
| (Increase) decrease in inventories | (0.0) | 11.2 | 2.7 | 34.0 | 7.5 | 4.2 | (7.3) | (36.7) |
| Increase (decrease) in trade accounts payable | (14.2) | (14.8) | (9.5) | (38.7) | 6.4 | 27.3 | 29.3 | 72.7 |
| Change in other net working capital etc. | 14.7 | (19.9) | (17.6) | (18.8) | 20.9 | (12.8) | (10.9) | (57.1) |
| Total (increase) decrease in net working capital etc. | 44.1 | (67.0) | (38.0) | (28.8) | 40.8 | 16.1 | (17.5) | (79.7) |
| Investment in property, plant and equipment | (12.4) | (32.9) | (50.2) | (50.4) | (22.0) | (48.9) | (58.9) | (76.3) |
| Lease liabilities paid | (2.0) | (4.0) | (6.1) | (8.1) | (2.0) | (4.0) | (5.9) | (8.2) |
| Investment in intangible assets | (0.1) | (1.7) | (2.9) | (4.0) | (0.5) | (16.2) | (17.3) | (35.3) |
| Operating free cash flows | 137.9 | 169.5 | 347.4 | 493.4 | 162.4 | 236.8 | 373.2 | 452.1 |
| as % of Revenue | 58.2% | 30.7% | 40.0% | 42.1% | 56.3% | 40.9% | 40.9% | 35.9% |
| Treasury activities (interest income/expenses, foreign exchange gains/losses etc.) | (9.7) | 5.2 | (8.8) | (6.2) | (12.8) | (6.7) | (1.3) | 12.3 |
| Tax paid | (41.0) | (40.0) | (100.4) | (100.5) | (106.9) | (107.2) | (190.7) | (191.1) |
| Free cash flows | 87.2 | 134.7 | 238.2 | 386.8 | 42.7 | 122.8 | 181.2 | 273.3 |
| Dividends paid | (65.0) | (65.5) | (133.0) | (133.2) | (93.4) | (93.8) | (299.5) | (299.4) |
| Transaction in own equity instruments | 0.1 | 0.1 | 0.1 | 0.2 | 0.1 | 0.1 | 0.1 | 0.1 |
| Net effect of currency translation on net cash | 3.3 | 7.4 | 1.0 | 3.7 | (1.2) | 2.1 | 4.3 | 9.4 |
| Net change in net cash | 25.6 | 76.7 | 106.3 | 257.3 | (51.7) | 31.3 | (113.9) | (16.6) |

Other cash adjustment on operating profit: Adjustments for all non-cash income and expense items other than amortization expenses and impairment included in operating profit (such as loss on inventory differences, allowance for doubtful accounts, stock option expenses, loss on asset retirement, and increase/decrease in provisions) as well as all non-operating income and expense cash flows relating to net operating assets (NOA) including proceeds from the sales of assets and utilization of provisions.

Operating free cash flow (Operating FCF): Pretax cash flow after adjusting changes in working capital and operating investments in assets (tangible and intangible) to “operating profit, net of operating cash adjustments,” which shows the company’s cash generation ability from operating activities.

Free cash flow (FCF): the ability to generate net cash from a management perspective after deducting tax, dividends, and other payments from operating FCF.

Net change in net cash: dividends paid, increases and decreases in marketable securities and interest-bearing debt, changes in equity are included.

The concepts of operating profit, operating FCF and Net operating assets (NOA) presented in the previous page are mutually consistent.

Free cash flow (FCF):

The consolidated statement of cash flows has been prepared in accordance with International Accounting Standard (IAS) No. 7, “Statement of Cash Flows.” FCF is a reconfiguration of the consolidated statement of cash flows as internal indicators and is identical to the indicators disclosed by Roche. Furthermore, no items from FCF have been excluded, as the Core results concept only applies to the income statement.

Key Performance Indicators

| | Units | Actual | | | | Actual | | | | Forecast (Jan 29th announced) |
|---|-----------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|---------------|----------------------------------|
| | | FY2024 | | | | FY2025 | | | | FY2026 |
| | | 1-3 | 1-6 | 1-9 | 1-12 | 1-3 | 1-6 | 1-9 | 1-12 | 1-12 |
| | | As of Mar. 31 | As of Jun. 30 | As of Sep. 30 | As of Dec. 31 | As of Mar. 31 | As of Jun. 30 | As of Sep. 30 | As of Dec. 31 | As of Dec. 31 |
| Total indicator | | | | | | | | | | |
| Core return on invested capital (Core ROIC) | % | 8.6 | 20.0 | 32.3 | 42.9 | 10.7 | 20.1 | 32.9 | 43.9 | |
| Return on invested capital (ROIC) | % | 8.4 | 19.6 | 31.7 | 41.8 | 10.5 | 20.2 | 31.4 | 42.3 | |
| Ratio of profit to total assets (ROA) | % | 3.9 | 9.3 | 14.8 | 18.7 | 4.5 | 8.7 | 13.9 | 18.6 | |
| Ratio of equity attributable to Chugai shareholders | % | 86.5 | 85.0 | 87.0 | 86.1 | 89.1 | 87.1 | 86.6 | 82.1 | |
| Ratio of equity attributable to Chugai shareholders (stock price base) | % | 500.6 | 456.5 | 551.1 | 521.5 | 523.0 | 543.5 | 486.0 | 549.5 | |
| Price book value ratio (PBR) | times | 5.8 | 5.4 | 6.3 | 6.1 | 5.9 | 6.2 | 5.6 | 6.7 | |
| Ratio of net income to equity attributable to Chugai shareholders (ROE) | % | 4.6 | 11.0 | 17.3 | 22.0 | 5.1 | 10.0 | 16.1 | 22.1 | |
| Margin indicator (Core) | | | | | | | | | | |
| ROS | % | 43.1 | 47.5 | 49.1 | 47.5 | 48.4 | 47.0 | 49.4 | 49.5 | 49.8 |
| COS ratio (vs. Prod. sales) | % | 35.5 | 33.0 | 32.5 | 33.9 | 33.7 | 34.2 | 33.1 | 32.6 | 34.9 |
| R&D cost ratio | % | 17.4 | 15.2 | 14.7 | 15.1 | 14.1 | 14.9 | 14.1 | 14.3 | 14.1 |
| Selling, general and administration cost ratio | % | 9.0 | 8.4 | 8.3 | 8.7 | 7.3 | 7.8 | 7.6 | 8.2 | 7.6 |
| Turnover indicator | | | | | | | | | | |
| Total asset turnover | % | 12.4 | 27.7 | 43.4 | 56.5 | 13.3 | 25.8 | 41.5 | 53.8 | |
| Working capital turnover | % | 26.9 | 58.5 | 92.8 | 126.7 | 30.7 | 59.7 | 93.1 | 122.2 | |
| Inventory turnover | Months | 11.4 | 9.9 | 10.0 | 8.5 | 8.0 | 8.0 | 8.0 | 9.1 | |
| Receivables turnover | Months | 3.1 | 3.7 | 3.2 | 3.1 | 2.9 | 3.1 | 3.3 | 3.5 | |
| Payables turnover | Months | 1.7 | 1.5 | 1.6 | 0.6 | 0.7 | 1.5 | 1.5 | 2.9 | |
| Fixed asset turnover | % | 53.5 | 124.1 | 193.6 | 260.1 | 61.4 | 120.0 | 190.6 | 253.2 | |
| PP&E turnover | % | 57.4 | 133.2 | 207.7 | 277.7 | 65.4 | 130.0 | 206.5 | 282.8 | |
| Intangible assets turnover | % | 1,202.2 | 2,749.9 | 4,269.7 | 6,205.5 | 1,639.5 | 2,261.4 | 3,504.1 | 3,474.6 | |
| Dividend / per stock indicator | | | | | | | | | | |
| Dividends per share (Half year) | Yen | 41 | | | | 125 | | | | 66 |
| Dividends per share (Year end) | Yen | 57 | | | | 147 | | | | 66 |
| Dividends per share (Full year) | Yen | 98 | | | | 272 | | | | 132 |
| Core earnings per share (diluted) | Yen | 46.16 | 115.15 | 183.09 | 241.31 | 60.30 | 117.57 | 194.44 | 274.02 | 295.00 |
| Core payout ratio (%) | % | 40.6 | | | | 99.3 | | | | 44.7 |
| Equity per share attributable to Chugai shareholders (BPS) | Yen | 997.97 | 1,064.55 | 1,094.71 | 1,155.56 | 1,158.97 | 1,206.25 | 1,148.51 | 1,230.91 | |
| Ratio of dividends to equity attributable to Chugai shareholders (DOE) | % | 9.1 | | | | 22.8 | | | | |
| Cashflow indicator | | | | | | | | | | |
| Cash conversion cycle (CCC) | Months | 12.8 | 12.1 | 11.6 | 11.0 | 10.1 | 9.6 | 9.8 | 9.7 | |
| Net cash turnover period | Months | 9.7 | 8.9 | 8.8 | 10.2 | 9.8 | 10.7 | 8.7 | 9.3 | |
| Number of employees | | | | | | | | | | |
| Investment on property, plant and equipment | Billions of yen | 15.5 | 25.1 | 37.7 | 52.8 | 23.8 | 38.9 | 49.7 | 63.4 | 68.0 |
| Depreciation | Billions of yen | 6.1 | 11.9 | 17.8 | 24.2 | 6.1 | 12.3 | 18.5 | 25.0 | 27.0 |
| Investment on intangible assets | Billions of yen | 0.3 | 1.6 | 3.8 | 4.4 | - | 16.3 | 17.6 | 39.9 | |
| Amortization | Billions of yen | 0.6 | 1.1 | 1.6 | 2.1 | 0.5 | 0.9 | 1.2 | 1.6 | |

Core ROIC: Core net operating profit after taxes / Net operating assets (Core ROIC is calculated by using Core Income taxes)

ROIC: Net operating profit after taxes / Net operating assets (Net operating profit after taxes = Operating profit – income taxes)

ROA: Net income / total assets, ROE: Net income attributable for Chugai shareholders / Equity attributable to Chugai shareholders

Total asset turnover: Revenue / Total asset, CCC: [Trade accounts receivable/Sales + (Inventories – Trade accounts payable)/Cost of sales]* passed months

Net cash turnover period: Net cash/Revenue * passed months

Core ROIC, ROIC, ROA, ROE, total asset turnover, working capital turnover, fixed asset turnover, PP&E turnover, and intangible assets turnover are not annualized.

The adjusted figures are used for calculating average NOA for Core ROIC and ROIC.

The annual dividend per share for the year ended December 31, 2025 consists of a regular dividend of 122 yen (half-year: 50 yen, year-end: 72 yen)

and a special dividend for the company's 100th Anniversary of 150 yen (half-year: 75 yen, year-end: 75 yen).

■ Oncology
 ■ Immunology
 ■ Neuroscience
 ■ Hematology
 ■ Ophthalmology
 ■ Other Diseases

Development Pipeline [Main table] (as of January 29, 2026)

| Development code Origin | Generic name Product name | Indication # Additional indication (Combination drug) | Country/region | Projected submission | Mode of Action Modality (Dosage form) | Partner |
|--|------------------------------|---|----------------|-------------------------|--|---------|
| Filed | | | | | | |
| ■ AF802/RG7853 in-house | alectinib Alecensa | ALK fusion / rearrangement gene-positive unresectable advanced or recurrent solid tumors # | Japan | June 2025 | ALK inhibitor Small molecule (oral) | — |
| ■ RG7446 Roche | atezolizumab Tecentriq | Adjuvant therapy for MRD- positive bladder cancer # | Japan | January 2026 | Engineered anti-PD-L1 monoclonal antibody Antibody (IV) | — |
| ■ RG7828 Roche | mosunetuzumab Lunsumio | Relapsed or refractory aggressive B-cell non- Hodgkin's lymphoma # (Polivy) # | Japan | May 2025 | Anti-CD20/CD3 bispecific antibody Antibody (SC) | Roche |
| ■ RG435 Roche | bevacizumab Avastin | Neurofibromatosis type 2 (NF2) # | Japan | August 2025 | Anti-VEGF humanized monoclonal antibody Antibody (IV) | — |
| Phase III | | | | | | |
| ■ AF802/RG7853 in-house | alectinib Alecensa | Maintenance treatment of NSCLC (stage III) after chemoradiotherapy # | Global | — | ALK inhibitor Small molecule (oral) | Roche |
| ■ RG7446 Roche | atezolizumab Tecentriq | HCC (intermediate stage) # (Avastin) # | Japan | 2027 | Engineered anti-PD-L1 monoclonal antibody Antibody (IV) | Roche |
| | | HCC (2nd Line) # (lenvatinib or sorafenib) | Japan | — | | Roche |
| ■ RG6171 Roche | giredestrant — | Breast cancer (adjuvant) | Japan | 2026 | SERD (Selective Estrogen Receptor Degradar) Small molecule (Oral) | Roche |
| | | Breast cancer (1st Line) (palbociclib) | Japan | 2026 | | Roche |
| | | Breast cancer (1st Line-3rd Line) (everolimus) | Japan | 2026 | | Roche |

■ Oncology
 ■ Immunology
 ■ Neuroscience
 ■ Hematology
 ■ Ophthalmology
 ■ Other Diseases

| Development code Origin | Generic name Product name | Indication # Additional indication (Combination drug) | Country/region | Projected submission | Mode of Action Modality (Dosage form) | Partner |
|--|------------------------------|---|----------------|-------------------------|---|--------------------|
| ■ RG7828 Roche | mosunetuzumab Lunsumio | Follicular lymphoma (2nd Line) # (lenalidomide) | Japan | 2026 | Anti-CD20/CD3 bispecific antibody Antibody (IV) | Roche |
| | | Previously untreated follicular lymphoma # | Japan | 2028 and beyond | | Roche |
| ■ RG6026 Roche | glofitamab — | Previously untreated large B- cell lymphoma (Polivy) | Japan | 2028 and beyond | Anti-CD20/CD3 bispecific antibody Antibody (IV) | Roche |
| ■ RG6330 Roche | divarasib — | NSCLC (2nd Line) | Japan | 2027 | KRAS G12C inhibitor Small molecule (Oral) | Roche |
| | | NSCLC (1st Line) | Japan | 2028 and beyond | | |
| ■ RG7159 GlycArt Biotechnology | obinutuzumab Gazyva | Lupus nephritis # | Japan | 2026 | Glycoengineered type II anti-CD20 monoclonal Antibody Antibody (IV) | Nippon shinyaku |
| | | Pediatric nephrotic syndrome # | Japan | 2026 | | Nippon shinyaku |
| | | Extra renal lupus # | Japan | 2027 | | Nippon shinyaku |
| ■ RG6299/ASO factor B Ionis Pharmaceuticals | sefaxersen — | IgA nephropathy | Japan | 2028 and beyond | Antisense oligonucleotide targeting <i>complement</i> <i>factor B</i> mRNA Nucleic acid (SC) | Roche |
| ■ RG6631 Roche | afimkibart — | Ulcerative colitis | Japan | 2027 | Anti-TL1A antibody Antibody (-) | Roche |
| | | Crohn's disease | Japan | 2028 and beyond | | |
| ■ — Bristol Myers Squibb | sparsentan — | IgA nephropathy | Japan | 2026 | Dual endothelin /angiotensin II receptor antagonist Small molecule (Oral) | — |

■ Oncology
 ■ Immunology
 ■ Neuroscience
 ■ Hematology
 ■ Ophthalmology
 ■ Other Diseases

| Development code Origin | | Generic name Product name | Indication # Additional indication (Combination drug) | Country/region | Projected submission | Mode of Action Modality (Dosage form) | Partner |
|----------------------------|----------------------------|--|---|----------------|-------------------------|--|----------|
| | SA237/RG6168 in-house | satralizumab Enspryng | Myelin oligodendrocyte glycoprotein antibody- associated disease (MOGAD) # | Global | 2026 | pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody Antibody (SC) | Roche |
| | | | Autoimmune encephalitis (AIE) # | Global | 2027 | | Roche |
| | RG6102 MorphoSys | trontinemab — | Alzheimer's disease | Japan | 2028 and beyond | Anti-amyloid beta/TfR1 fusion protein Antibody (IV) | Roche |
| | RG6356/SRP-9001 Sarepta | delandistrogene moxeparvovec Elevydis | Duchenne muscular dystrophy (DMD) (non-ambulatory) # | Japan | 2028 and beyond | Microdystrophin gene therapy Gene therapy (IV) | Sarepta* |
| | SKY59/RG6107 in-house | crovalimab PiaSky | Atypical hemolytic uremic syndrome (aHUS) # | Global | 2026 | Anti-C5 recycling antibody Antibody (SC) | Roche |
| | ACE910/RG6013 In-house | emicizumab Hemlibra | Type 3 von Willebrand disease # | Global | 2027 | Anti-coagulation factor IXa/X humanized bispecific monoclonal antibody Antibody (SC) | Roche |
| | SA237/RG6168 in-house | satralizumab Enspryng | Thyroid eye disease (TED) # | Global | 2026 | pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody Antibody (SC) | Roche |
| | RG6179 Roche | vamikibart — | Noninfectious uveitic macular edema (UME) | Japan | 2026 | Anti-IL-6 monoclonal antibody Antibody (vitreous injection) | Roche |
| | RG7716 Roche | faricimab Vabysmo | Non-proliferative diabetic retinopathy (NPDR) # | Japan | 2028 and beyond | Anti-VEGF/Anti-Ang-2 bispecific antibody Antibody (vitreous injection) | — |

| Development code Origin | | Generic name Product name | Indication # Additional indication (Combination drug) | Country/region | Projected submission | Mode of Action Modality (Dosage form) | Partner |
|----------------------------|--------------------------------------|------------------------------|---|----------------|-------------------------|---|--------------------------------|
| | RG6615 Alnylam Pharmaceuticals | zilebesiran — | Hypertension | Japan | 2028 and beyond | RNAi therapeutic targeting angiotensinogen (AGT) RNAi (SC) | Alnylam Pharmace uticals |
| Phase II/III | | | | | | | |
| | GYM329/ RG6237 in-house | emugrobart — | Spinal muscular atrophy (SMA) (Evrysdi) | Global | 2028 and beyond | Anti-latent myostatin sweeping antibody Antibody (SC) | Roche |
| Phase II | | | | | | | |
| | RG6026 Roche | glofitamab — | Relapsed or refractory diffuse large B-cell lymphoma | Japan | 2026 | Anti-CD20/CD3 bispecific antibody Antibody (IV) | — |
| | | | Relapsed or refractory mantle cell lymphoma | Japan | 2028 and beyond | | — |
| | GYM329/ RG6237 in-house | emugrobart — | Facioscapulohumeral muscular dystrophy (FSHD) | Global | 2028 and beyond | Anti-latent myostatin sweeping antibody Antibody (SC) | Roche |
| | SA237/RG6168 in-house | satralizumab Enspryng | Duchenne muscular dystrophy (DMD) # | Global | 2028 and beyond | pH-dependent binding humanized anti-IL-6 receptor monoclonal antibody Antibody (SC) | Roche |
| | RG6042 Ionis Pharmaceuticals | tominersen — | Huntington's disease | Japan | — | Antisense oligonucleotide targeting <i>HTT</i> mRNA Nucleic acid (IV) | Roche |
| | GYM329/RG6237 In-house | emugrobart — | Obesity | Global | 2028 and beyond | Anti-latent myostatin sweeping antibody Antibody (SC) | Roche |
| Phase I/II | | | | | | | |

■ Oncology
 ■ Immunology
 ■ Neuroscience
 ■ Hematology
 ■ Ophthalmology
 ■ Other Diseases

| Development code Origin | | Generic name Product name | Indication # Additional indication (Combination drug) | Country/region | Projected submission | Mode of Action Modality (Dosage form) | Partner |
|----------------------------|-------------------------------|---|--|----------------|-------------------------|---|---------|
| | RG6114 Roche | inavolisib — | PIK3CA-mutated breast cancer (palbociclib + fulvestrant) | Japan | — | PI3Kα inhibitor Small molecule (Oral) | Roche |
| | NXT007/ RG6512 in-house | — — | Hemophilia A | Global | 2028 and beyond | Anti-coagulation factor IXa/X bispecific antibody Antibody (SC) | Roche |
| | RG6321 Roche | ranibizumab (Port Delivery Platform with ranibizumab) — | Neovascular age-related macular degeneration | Japan | 2026 | Humanized anti-VEGF monoclonal antibody Fragment Fab | — |
| | | | Diabetic macular edema | Japan | 2026 | Antibody (injection via implant) | — |
| Phase I | | | | | | | |
| | GC33 in-house | codrituzumab — | HCC | Global | — | Anti-Glypican-3 humanized monoclonal antibody Antibody (IV) | — |
| | ALPS12 in-house | clesitamig — | Solid tumors | Global | — | Anti-DLL3/CD3/CD137 trispecific antibody Antibody (IV) | — |
| | ROSE12 in-house | — — | Solid tumors | Global | — | Anti-CTLA-4 Switch antibody Antibody (IV) | — |
| | MINT91 in-house | — — | Solid tumors | Global | — | - Small molecule (Oral) | — |
| | AUBE00 In-house | — — | Solid tumors | Global | — | Pan-KRAS inhibitor Macrocyclic peptide (Oral) | — |
| | RG7421 Exelixis | cobimetinib — | Solid tumors | Japan | — | MEK inhibitor Small molecule (Oral) | — |
| | RG6160 Roche | cevostamab — | Relapsed or refractory multiple myeloma | Japan | — | Anti-FcRH5/CD3 bispecific antibody Antibody (IV) | — |

■ Oncology
 ■ Immunology
 ■ Neuroscience
 ■ Hematology
 ■ Ophthalmology
 ■ Other Diseases

| Development code Origin | Generic name Product name | Indication # Additional indication (Combination drug) | Country/region | Projected submission | Mode of Action Modality (Dosage form) | Partner |
|--|------------------------------|---|----------------|-------------------------|--|---------|
| ■ DONQ52 in-house | — — | Celiac disease | Global | — | Anti-HLA-DQ2.5/gluten peptides multispecific antibody Antibody (SC) | — |
| ■ RAY121 in-house | — — | Autoimmune disease | Global | — | Anti-C1s recycling antibody Antibody (SC) | — |
| ■ RG7935 Prothena | prasinezumab — | Parkinson's disease | Japan | — | Anti- α -synuclein monoclonal antibody Antibody (IV) | — |
| ■ REVN24 in-house | — — | Acute diseases | Global | — | — Small molecule (IV) | — |
| ■ RAY121 in-house | — — | — | Global | — | Anti-C1s recycling antibody Antibody (-) | — |
| Development Discontinued | | | | | | |
| Development code Origin | Generic name Product name | Indication # Additional indication (Combination drug) | Country/region | Development stage | Mode of Action Modality (Dosage form) | Partner |
| ■ RG7446 Roche | atezolizumab Tecentriq | NSCLC (perioperative) # | Japan | Phase III | Engineered anti-PD-L1 monoclonal antibody Antibody (IV) | Roche |
| ■ BRY10 In-house | — — | Chronic diseases | Global | Phase I | — Antibody (SC) | — |

In principle, completion of first dose is regarded as pipeline entry into each phase of clinical studies.

* Sarepta manages the global study including Japan

Changes from the last announcement on October 24, 2025

Oncology

- RG7446 Filed (Unresectable thymic carcinoma) → Approved
- RG7446 Phase III (Muscle-invasive bladder cancer (adjuvant))
→ Filed (Adjuvant therapy for MRD (molecular residual disease)-positive bladder cancer)
- RG7446 Phase III (NSCLC (perioperative)) → Development discontinued
- RG6330 Phase I/II (NSCLC (1st Line)) → Phase III

Immunology

- sparsentan Domestic Phase III (IgA nephropathy: development started)

Neuroscience

- RG6102 Phase I/II (Alzheimer's disease) → Phase III

Other Diseases

- RG6615 Phase I/II (Hypertension) → Phase III
- BRY10 Phase I (Chronic diseases) → Development discontinued

R&D Activities

For the changes during the FY2025 (January 1 – December 31), please refer to page 5 of “CONSOLIDATED FINANCIAL STATEMENTS (IFRS) (Non-Audited) (for the fiscal year 2025).”

Changes from January 1, 2026 to January 29, 2026 are as follows:

Oncology

- We filed for an antineoplastic agent / humanized anti-PD-L1 monoclonal antibody RG7446 (Product name: Tecentriq) for an additional indication of adjuvant therapy for MRD-positive bladder cancer in January 2026.
- We started global Phase III study for a KRAS G12C inhibitor RG6330 for the treatment of NSCLC (1st Line) in January 2026.

Development Pipeline [Attached table] (Major Chugai originated developments licensed out to 3rd parties excluding Roche)

| Development code licensee/In-house | Generic name Product name | Indication # Additional Indication (combination) | Stage Country/region | Mode of Action Modality (Dosage form) | Licensee (Granted rights) |
|---------------------------------------|------------------------------|--|--------------------------------------|--|--|
| VS-6766/CKI27 | avutometinib AVMAPKI | KRAS-mutated recurrent LGSOC (defactinib) | Phase III Overseas, U.S. | RAF/MEK clamp Small molecule (Oral) | Verastem Oncology (exclusive global license for the manufacturing, development and marketing) |
| | | | Phase II Japan | | |
| | | mPDAC (1st line) (defactinib+chemotherapy) | Phase I/II U.S. | | |
| — /CIM331 | nemolizumab NEMLUVIO | Chronic pruritus of unknown origin (CPUO) | Phase II Overseas | Anti-IL-31 receptor A humanized monoclonal antibody Antibody (SC) | Galderma (exclusive global license for the development and marketing excluding Japan) |
| LY3502970/OWL833 | orforglipron — | Type 2 diabetes | Phase III Global | Oral non-peptidic GLP-1 receptor agonist Small molecule (Oral) | Eli Lilly and Company (worldwide development and commercialization rights) |
| | | Obesity | Phase III Global Filed U.S. | | |
| | | Obstructive sleep apnea | Phase III Global | | |
| | | Hypertension | Phase III Global | | |
| | | Osteoarthritis | Phase III Global | | |
| | | Stress urinary incontinence | Phase III Global | | |
| | | Investigation of the effect of orforglipron on the incidence of major adverse cardiovascular events* | Phase III Global | | |

| | | | | | |
|--------------|--------|-----------------------------|---------------------|--|--|
| | | Peripheral arterial disease | Phase III Global | | |
| AP306/EOS789 | — — | Hyperphosphatemia | Phase II China | Oral inhibitor of phosphate transporters Small molecule (Oral) | Alebund (exclusive global license for the manufacturing, development and marketing) |

*In Participants with established atherosclerotic cardiovascular disease and/or chronic kidney disease

Progress made in R&D activities of major Chugai originated developments licensed out to 3rd party excluding Roche during the period from January 1, 2025 to January 29, 2026 was as follows.

- In Europe, Galderma obtained regulatory approval for the anti-IL-31 receptor A humanized monoclonal antibody CIM331 (Product name in Europe: NEMLUVIO (nemolizumab)) for moderate-to-severe atopic dermatitis and prurigo nodularis in February 2025. It started a global Phase II study for the treatment of chronic pruritus of unknown origin (CPUO) in Q4 2025.
- In the U.S., Verastem obtained regulatory approval under the accelerated approval pathway for the RAF/MEK clamp VS-6766/CKI27 (Product name in the U.S.: AVMAPKI) for *KRAS*-mutated recurrent LGSOC (combination with defactinib) in May 2025. It decided to discontinue the development for advanced *KRAS G12C*-mutated non-small cell lung cancer in December 2025.
- Eli Lilly and Company started a global Phase III study for the oral non-peptidic GLP-1 receptor agonist LY3502970/OWL833 (orforglipron) for the treatment of hypertension in Q3 2025, for the treatment of osteoarthritis, stress urinary incontinence, Investigation of the effect of orforglipron on the incidence of major adverse cardiovascular events in Q4 2025, and for the treatment of peripheral arterial disease in Q1 2026, respectively. In addition, it has filed for approval to the U.S. Food and Drug Administration for the treatment of obesity in Q4 2025.
- PI3K Class I inhibitor "PA799" was granted exclusive worldwide rights for manufacturing, development, and commercialization to Menarini Group in November 2016, but all licensing rights were returned to Chugai in June 2025.

Response to Requests from the MHLW Review Committee on Unapproved Drugs and Indications with High Medical Needs (As of January 29, 2026)

| Development Request | Product | Indication | Development Status |
|----------------------------|---------|---|---|
| Fourth development request | Xeloda* | Neuroendocrine tumor | Submitted company opinion and waiting for evaluation by committee |
| | Avastin | Cerebral edema induced by radiation necrosis | Submitted company opinion and waiting for evaluation by committee |
| | Mircera | Anemia associated with chronic kidney disease (CKD) in pediatric patients 3 months of age and older | Submitted company opinion and waiting for evaluation by committee |

*Transferred the marketing authorization holder to CHEPLAPHARM K.K. as of February 1, 2024

Major Clinical Trials

| Project | Expected indication | Study design | Study name | Stage | CT information |
|-------------------------------|--|--|------------|----------------------|----------------|
| Oncology | | | | | |
| AF802/RG7853 (Alecensa) | Maintenance treatment of NSCLC (stage III) after chemoradiotherapy | ALK fusion-positive: Alecensa vs. durvalumab | HORIZON01 | Phase III | NCT05170204 |
| RG7446 (Tecentriq) | HCC (intermediate stage) | Tecentriq + Avastin + TACE vs. TACE | TALENTACE | Phase III | NCT04803994 |
| | HCC [2nd line] | Tecentriq + lenvatinib or sorafenib vs. lenvatinib or sorafenib | IMbrave251 | Phase III | NCT04770896 |
| RG6171/SERD (giredestrant) | Breast cancer (adjuvant) | HR positive: RG6171 vs. endocrine therapy | lidERA | Phase III | NCT04961996 |
| | Breast cancer [1st line] | HR positive: RG6171 + palbociclib vs. letrozole + palbociclib | persevERA | Phase III | NCT04546009 |
| | Breast cancer [1st line-3rd line] | HR positive: RG6171 + everolimus vs. endocrine therapy+ everolimus | evERA | Phase III | NCT05306340 |
| RG7828 (Lunsumio) | Follicular lymphoma [2nd line] | Lunsumio + lenalidomide vs. Rituxan + lenalidomide | CELESTIMO | Phase III | NCT04712097 |
| | Relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma | Lunsumio + Polivy vs. Rituxan + chemotherapy | SUNMO | Phase III | NCT05171647 |
| | Previously untreated follicular lymphoma | Lunsumio + lenalidomide vs. Rituxan + chemotherapy | — | Phase III (domestic) | JRCT2011240017 |
| RG6026 (glofitamab) | Previously untreated large B-cell lymphoma | RG6026 + Polivy + Rituxan + chemotherapy vs. Polivy + Rituxan + chemotherapy | SKYGLO | Phase III | NCT06047080 |
| | Relapsed or refractory diffuse large B-cell lymphoma | RG6026 + gemcitabine + oxaliplatin (GemOx) (single arm) | — | Phase II (domestic) | JRCT2051250036 |
| | Relapsed or refractory mantle cell lymphoma | RG6026 (single arm) | | | |

| Project | Expected indication | Study design | Study name | Stage | CT information |
|--|---|--|---------------------------|--------------------------|----------------------------|
| RG6330 (divarasib) | NSCLC [2nd line] | RG6330 vs. sotorasib or adagrasib | Krascendo 1 | Phase III | NCT06497556 |
| | NSCLC [1st line] | RG6330 + pembrolizumab vs. pembrolizumab +chemotherapy | Krascendo 2 | Phase III | NCT06793215 |
| RG6114 (inavolisib) | <i>PIK3CA</i> -mutated breast cancer | RG6114 + palbociclib + fulvestrant (single arm) | — | Phase I/II (domestic) | JRCT2031250161 |
| Immunology | | | | | |
| RG7159 (Gazyva) | Lupus nephritis | Standard of care treatment ± Gazyva | — | Phase III (domestic) | JRCT2011210059 |
| | Pediatric nephrotic syndrome | Gazyva vs. MMF | INShore | Phase III | NCT05627557 |
| | Extra renal lupus | Gazyva vs. Placebo | — | Phase III (domestic) | JRCT2071230031 |
| RG6299 (sefaxersen) | IgA nephropathy | RG6299 vs. Placebo | IMAGINATION | Phase III | NCT05797610 |
| RG6631 (afimkibart) | Ulcerative colitis | RG6631 vs. Placebo | Ametrine-1 | Phase III | NCT06589986 |
| | Crohn's disease | RG6631 vs. Placebo | SIBERITE-1 | Phase III | NCT06819878 |
| sparsentan | IgA nephropathy | sparsentan (single arm) | — | Phase III (domestic) | JRCT2051240070 |
| Neuroscience | | | | | |
| SA237/RG6168 (Enspryng) | Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD) | Enspryng vs. Placebo | METEOROID | Phase III | NCT05271409 |
| | Autoimmune encephalitis (AIE) | Enspryng vs. Placebo | CIELO | Phase III | NCT05503264 |
| GYM329/RG6237 (emugrobarf) | Spinal muscular atrophy (SMA) | Evrysdi ± GYM329 | MANATEE | Phase II/III | NCT05115110 |
| RG6356/SRP-9001 (delandistrogene moxeparvovec) | Duchenne muscular dystrophy (DMD) (non-ambulatory) | RG6356 vs. Placebo | ENVISION | Phase III | NCT05881408 |
| RG6102 (trontinemab) | Alzheimer's disease | RG6102 vs. Placebo | TRONTIER 1/ TRONTIER 2 | Phase III | NCT07169578 NCT07170150 |
| Hematology | | | | | |

| Project | Expected indication | Study design | Study name | Stage | CT information |
|---|--|---|-------------------------|--------------------------|----------------------------|
| SKY59/RG6107 (PiaSky) | Atypical hemolytic uremic syndrome (aHUS) | PiaSky (single arm) | COMMUTE-a | Phase III | NCT04861259 |
| | | PiaSky (single arm) | COMMUTE-p | Phase III | NCT04958265 |
| ACE910/RG6013 (Hemlibra) | Type 3 von Willebrand disease | Hemlibra vs. On-demand therapy (standard of care treatment) | WILL-EMI | Phase III | NCT06998524 |
| Ophthalmology | | | | | |
| SA237/RG6168 (Enspryng) | Thyroid eye disease (TED) | Enspryng vs. Placebo | SatraGO-1/ SatraGO-2 | Phase III | NCT05987423 NCT06106828 |
| RG6179 (vamikibart) | Noninfectious uveitic macular edema | RG6179 vs. sham | Sandcat | Phase III | NCT05642325 |
| RG7716 (Vabysmo) | Non-proliferative diabetic retinopathy | RG7716 vs. sham | AZUSA | Phase III (domestic) | jRCT2071250009 |
| RG6321 (ranibizumab (Port Delivery Platform with ranibizumab)) | Neovascular age-related macular degeneration / Diabetic macular edema | RG6321 (single arm) | TEIEN | Phase I/II (domestic) | jRCT2071210073 |
| Other diseases | | | | | |
| RG6615 (zilebesiran) | Hypertension | RG6615 vs. Placebo | ZENITH | Phase III | NCT07181109 |

Clinical Trials of In-House Developed Projects

Excluding projects listed in Major Clinical Trials among the projects listed in the development pipeline. Only clinical trials led by Chugai or Roche are listed.

| Project | Expected indication | Stage | Enrollment* as of December 31, 2025 | Study start | CT information |
|-----------------|---------------------|--------------------|--|----------------|----------------|
| Oncology | | | | | |
| GC33 | HCC | Phase I | 27 | November, 2008 | NCT00746317 |
| | | Phase I | 42 | October, 2009 | NCT00976170 |
| | | Phase I (domestic) | 18 | October, 2010 | jRCT2080221218 |
| | | Phase II | 185 | May, 2012 | NCT01507168 |
| | | Phase I | 27 | August, 2016 | jRCT2080223270 |

| Project | Expected indication | Stage | Enrollment* as of December 31, 2025 | Study start | CT information |
|-------------------------------|---|---|--|-----------------|---------------------|
| ALPS12 (clesitamig) | Solid tumors | Phase I | 122 | October, 2025 | NCT07107490 |
| ROSE12 | Solid tumors | Phase Ia/Ib | 219 | June, 2023 | NCT05907980 |
| MINT91 | Solid tumors | Phase I | 122 | April, 2025 | jRCT2031240713 |
| AUBE00 | Solid tumors | Phase I | 100 | June, 2025 | jRCT2031250094 |
| Immunology | | | | | |
| DONQ52 | Celiac disease | Phase Ia/Ib | 56 | September, 2022 | NCT05425446 |
| | | Phase Ic | 63 | July, 2024 | ACTRN12624000316505 |
| RAY121 | Autoimmune disease | Phase Ib | 144 | August, 2024 | NCT06723106 |
| Neuroscience | | | | | |
| GYM329/RG6237 (emugrobart) | Facioscapulohumeral muscular dystrophy (FSHD) | Phase II | 51 | March, 2023 | NCT05548556 |
| SA237/RG6168 (Enspryng) | Duchenne muscular dystrophy (DMD) | Phase II | 50 | April, 2025 | NCT06450639 |
| Hematology | | | | | |
| NXT007/RG6512 | Hemophilia A | Phase I/II (domestic) | 124 | August, 2019 | jRCT2080224835 |
| | | Phase I (domestic) (only healthy adults) | 30 | May, 2022 | jRCT2031220050 |
| | | Phase I/II | 60 | October, 2023 | NCT05987449 |
| Other diseases | | | | | |
| REVN24 | Acute diseases | Phase I (domestic) (only healthy adults) | 210 | October, 2023 | jRCT2071230074 |
| | | | | | |
| RAY121 | — | Phase I (only healthy adults) | 36 | March, 2025 | 2024-515151-38-00 |
| GYM329/RG6237 (emugrobart) | Obesity | Phase II | 285 | May, 2025 | NCT06965413 |

* The number of enrollments is listed based on public information and generally refers to estimations or actual results.

FoundationOne CDx Cancer Genomic Profile: companion diagnostic indications (as of January 29, 2026)

| Alterations | Cancer type | Relevant drugs |
|---|----------------------|---|
| Activating <i>EGFR</i> alterations | NSCLC | afatinib maleate, erlotinib, gefitinib, osimertinib mesilate, dacomitinib hydrate |
| <i>EGFR</i> exon 20 T790M alteration | | osimertinib mesilate |
| <i>ALK</i> fusion genes | | alectinib, crizotinib, ceritinib, brigatinib |
| <i>ROS1</i> fusion genes | | entrectinib |
| <i>MET</i> exon 14 skipping alterations | | capmatinib hydrochloride hydrate |
| <i>BRAF</i> V600E and V600K alterations | Malignant melanoma | dabrafenib mesilate, trametinib dimethyl sulfoxide, vemurafenib, encorafenib, binimetinib |
| <u><i>BRAF</i> V600 alterations and <i>BRAF</i> fusion genes</u> | <u>Glioma</u> | <u>tovorafenib</u> |
| <i>ERBB2</i> copy number alterations (HER2 gene amplification positive) | Breast cancer | trastuzumab |
| <i>AKT1</i> alterations | | capivasertib |
| <i>PIK3CA</i> alterations | | |
| <i>PTEN</i> alterations | | |
| <i>KRAS/NRAS</i> wildtype | Colorectal cancer | cetuximab (genetical recombination), panitumumab (genetical recombination) |
| Microsatellite instability-high | | nivolumab (genetical recombination) |
| Microsatellite instability-high | Solid tumors | pembrolizumab (genetical recombination) |
| Tumor mutational burden-high | | pembrolizumab (genetical recombination) |
| <i>NTRK1/2/3</i> fusion genes | | entrectinib, larotrectinib sulfate, repotrectinib |
| <i>RET</i> fusion genes | | seelpercatinib |
| <u><i>ALK</i> fusion genes</u> | | <u>alectinib</u> |
| <i>BRCA1/2</i> alterations | Ovarian cancer | olaparib |
| <i>BRCA1/2</i> alterations | Prostate cancer | olaparib, talazoparib tosilate |
| <i>FGFR2</i> fusion genes | Biliary tract cancer | pemigatinib |

* Underlined are the companion diagnostic features and relevant drugs currently under application for regulatory approval.

FoundationOne Liquid CDx Cancer Genomic Profile: companion diagnostic indications (as of January 29, 2026)

| Alterations | Cancer type | Relevant drugs |
|---|-----------------|--|
| Activating <i>EGFR</i> alterations | NSCLC | afatinib maleate, erlotinib, gefitinib, osimertinib mesilate |
| <i>EGFR</i> exon 20 T790M alteration | | osimertinib mesilate |
| <i>ALK</i> fusion genes | | alectinib, crizotinib, ceritinib |
| <i>ROS1</i> fusion genes | | entrectinib |
| <i>MET</i> exon 14 skipping alterations | | capmatinib hydrochloride hydrate |
| <i>NTRK1/2/3</i> fusion genes | Solid tumors | entrectinib |
| <i>BRCA1/2</i> alterations | Prostate cancer | olaparib |